Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.04 |
---|---|
High | 3.29 |
Low | 2.95 |
Bid | 3.03 |
Offer | 3.25 |
Previous close | 2.97 |
Average volume | 1.47m |
---|---|
Shares outstanding | 120.03m |
Free float | 88.68m |
P/E (TTM) | -- |
Market cap | 356.49m USD |
EPS (TTM) | -2.05 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Prime Medicine to Participate in Upcoming Investor Conferences
- Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
- Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
- Prime Medicine Unveils Strategically Focused Pipeline
- Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
- Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Prime Medicine to Present at Upcoming Investor Conferences
- Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
More ▼